XLON
OPTI
Market cap16mUSD
Jul 15, Last price
12.00GBP
1D
5.45%
1Q
-33.33%
Jan 2017
-80.33%
IPO
-99.61%
Name
OptiBiotix Health PLC
Chart & Performance
Profile
OptiBiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; SlimBiome Medical, a natural supplement for weight management; CholBiome, a food supplement for maintaining healthy levels of cholesterol; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galactooligosaccharid that is used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; WellBiome, a functional fibre and mineral blend that supports health & wellbeing by promoting the diversity of the gut microbiome; and Sweetbiotix, a sweetener for use in food and beverages. The company's products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. OptiBiotix Health Plc was founded in 2012 and is headquartered in York, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑11 | 2017‑11 | 2016‑11 | 2015‑11 | |
Income | |||||||||
Revenues | 644 40.92% | 457 -79.35% | |||||||
Cost of revenue | 1,513 | 1,275 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (869) | (818) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (4) | (146) | |||||||
Tax Rate | |||||||||
NOPAT | (865) | (672) | |||||||
Net income | (2,039) -178.82% | 2,587 -58.68% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 485 | ||||||||
BB yield | -3.93% | ||||||||
Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (7,328) | (9,203) | |||||||
Cash flow | |||||||||
Cash from operating activities | (1,527) | (1,109) | |||||||
CAPEX | (168) | ||||||||
Cash from investing activities | 1,110 | (331) | |||||||
Cash from financing activities | 485 | ||||||||
FCF | (655) | 127 | |||||||
Balance | |||||||||
Cash | 635 | 1,052 | |||||||
Long term investments | 6,693 | 8,151 | |||||||
Excess cash | 7,296 | 9,180 | |||||||
Stockholders' equity | 3,642 | 6,447 | |||||||
Invested Capital | 5,230 | 4,458 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 90,191 | 93,213 | |||||||
Price | 0.27 101.89% | 0.13 -71.20% | |||||||
Market cap | 24,126 95.34% | 12,351 -71.90% | |||||||
EV | 16,798 | 3,148 | |||||||
EBITDA | (664) | (594) | |||||||
EV/EBITDA | |||||||||
Interest | 5,013 | ||||||||
Interest/NOPBT |